The results of this study indicate that MAP4K4 inhibition with GNE-495 is a promising strategy for preventing NSCLC metastasis and could be a valuable therapeutic approach for patients with elevated HMMR levels. This evidence concerns the gene MAP4K4 and non-small cell lung carcinoma.